Johnson & Johnson reported worldwide sales of $320 million for RYBREVANT® and LAZCLUZE® (lazertinib) in Q3 2026, representing 62.3% year-on-year growth.
The combined products generated $866 million in worldwide sales during the first nine months of 2026, up 67.4% from the same period in 2025.
LAZCLUZE®, originally developed by Yuhan Corporation and licensed to Janssen Biotech, Inc. in 2018, is a third-generation oral EGFR tyrosine kinase inhibitor approved in combination with RYBREVANT® for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer.
These results highlight the continued growth of RYBREVANT®/LAZCLUZE® franchise and mark another milestone for Yuhan’s contribution to global oncology innovation.
Source: Johnson & Johnson, Q3 2026 Earnings Release (10/13/2026)